AirDuo RespiClick
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $9,319 | 9 | 1 |
| 2023 | $82,725 | 8 | 2 |
| 2022 | $8,930 | 5 | 3 |
| 2021 | $234,719 | 283 | 198 |
| 2020 | $61.39 | 5 | 5 |
| 2018 | $2.0M | 488 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.1M | 497 | 89.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $225,027 | 100 | 9.6% |
| Food and Beverage | $14,383 | 174 | 0.6% |
| Travel and Lodging | $6,951 | 27 | 0.3% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients Aged 4 Through 11 Years With Persistent Asthma | Teva Pharmaceuticals USA, Inc. | $2.0M | 1 |
| Utilizing Advances in Digital Inhaler Technology to Understand Heterogeneous Treatment Responses to Biologics in Severe Asthma | Teva Pharmaceuticals USA, Inc. | $81,523 | 0 |
| CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma | Teva Pharmaceuticals USA, Inc. | $7,870 | 0 |
Top Doctors Receiving Payments for AirDuo RespiClick
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Miami, FL | $2.1M | 492 |
| , MD | Allergy & Immunology | Forest, VA | $43,180 | 28 |
| , MD | Pediatric Pulmonology | Oklahoma City, OK | $24,443 | 5 |
| , M.D | Allergy & Immunology | Fishers, IN | $22,912 | 10 |
| , M.D | Allergy | Montgomery, AL | $11,115 | 5 |
| , M.D | Specialist | Stockton, CA | $9,531 | 4 |
| , MD | Allergy & Immunology | Chicago, IL | $8,320 | 4 |
| , M.D | Allergy & Immunology | San Antonio, TX | $6,786 | 3 |
| , M.D | Allergy & Immunology | Powderly, KY | $6,324 | 3 |
| , MD | Pulmonary Disease | San Antonio, TX | $6,250 | 2 |
| , M.D | Allergy | Pittsburgh, PA | $6,240 | 3 |
| , MD | Pulmonary Disease | Murray, UT | $5,720 | 2 |
| , MD | Pulmonary Disease | Westminster, CA | $5,372 | 3 |
| , M.D | Allergy & Immunology | Burke, VA | $5,040 | 3 |
| , MD | Allergy & Immunology | Pikeville, KY | $5,040 | 3 |
| , MD | Allergy & Immunology | Belle Mead, NJ | $4,698 | 5 |
| , MD-PHD | Allergy & Immunology | New York, NY | $4,160 | 2 |
| , M.D | Allergy & Immunology | Canton, MI | $4,160 | 2 |
| , MD | Pediatrics | Lafayette, IN | $4,160 | 2 |
| , M.D., MSC | Internal Medicine | La Jolla, CA | $3,760 | 2 |
| , M.D | Internal Medicine | San Diego, CA | $3,567 | 2 |
| , PA-C | Physician Assistant | South Easton, MA | $3,518 | 8 |
| , M.D | Specialist | Upper Marlboro, MD | $3,360 | 2 |
| , MD PHD | Specialist | Redondo Beach, CA | $2,985 | 2 |
| , M.D | Allergy & Immunology | Ocean, NJ | $2,876 | 2 |
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $2.3M
- Total Doctors 205
- Transactions 798
About AirDuo RespiClick
AirDuo RespiClick is a drug associated with $2.3M in payments to 205 healthcare providers, recorded across 798 transactions in the CMS Open Payments database. The primary manufacturer is Teva Pharmaceuticals USA, Inc..
Payment data is available from 2018 to 2024. In 2024, $9,319 was paid across 9 transactions to 1 doctors.
The most common payment nature for AirDuo RespiClick is "Unspecified" ($2.1M, 89.5% of total).
AirDuo RespiClick is associated with 3 research studies, including "A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients Aged 4 Through 11 Years With Persistent Asthma" ($2.0M).